BEHANDLUNG VON KREBS

Patent europeic · EP4096717 · En vigur

Inscripziun en il register

Numer da publicaziun
EP4096717
Numer da la dumonda
EP21702624
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
28-01-2021
Publitgà
07-12-2022
Concedì
11-12-2024
La protecziun finescha il pli tard
27-01-2041
Proxima taxa annuala scadenta
31-01-2027
Classas IPC
A61K 47/68 (2017.01)
A61P 35/00 (2006.01)
Prioritad
US 202062968175 P 31.01.2020
Dumonda PCT
PCT/EP2021/051938 28.01.2021
Publicaziun PCT
WO2021/151984 05.08.2021
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-02-2026

    Midada

    Published in Swissreg on 01.02.2026

  2. 24-09-2025

    Midada

    Published in Swissreg on 24.09.2025

  3. 17-09-2025

    Midada

    Published in Swissreg on 17.09.2025

  4. 06-03-2025

    Midada

    Published in Swissreg on 06.03.2025

  5. 11-12-2024

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 11.12.2024

Partidas

Possessur

Innate Pharma

117, Avenue de Luminy, 13009 Marseille, FR

Inventur

KRAIEM, Manel

13011 MARSEILLE, FR

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.